Presented to the Market Access Leadership team about my key learnings in the Trade/Payer Rotation, I recently presented my key learnings in the Trade/Payer Rotation to the Market Access Leadership team. 

During this rotation, I gained an understanding of essential concepts like WAC Pricing, ASP, and ROI on Payer Contracts. Additionally, I developed skills in problem identification and implementing new tools while also improving my time management abilities, which included expansion of knowledge like WAC Pricing, ASP, and ROI on Payer Contracts, the ability to identify problems and deliver on a new tool, and how to effectively time manage. 

The Inflation Reduction Act (IRA) is the centerpiece of the Biden administration’s agenda to address the spiraling drug prices that have long burdened the American healthcare system. The following paper examines the IRA, particularly its provisions that permit the Centers for Medicare & Medicaid Services (CMS) to negotiate drug prices with pharmaceutical manufacturers. Some have celebrated this move as a victory over “Big Pharma." However, others have criticized the IRA as a potential infringement on their constitutional rights and a threat to medical innovation. Through a detailed analysis of the Fifth Amendment’s Takings Clause challenge to the IRA, the paper argues that the IRA's drug pricing provisions are not a taking under the Fifth Amendment.  

Represented Seton Hall Law for the L. Edward Bryant, Jr. National Health Law Transactional Competition. 

The competition required me to prepare a brief and a presentation on the topic of a nonprofit hospital merging with a for-profit entity. I had to consider the potential compliance, regulatory, and business aspects of this merger.

The Inflation Reduction Act (IRA) is reshaping the pharmaceutical landscape, sparking both intended and unintended market responses. This article explores how manufacturers are adapting, highlighting three key trends: launching drugs at higher initial list prices to offset profit reductions, reducing investment in high-value or multi-indication drugs, and facing altered prescribing habits due to Medicare Part B's revised reimbursement structure.

The IRA introduces transformative measures like Medicare drug price negotiation and inflation-based penalties, aiming to curb costs. However, these provisions may inadvertently incentivize higher launch prices, limit research into additional drug indications, and shift provider behavior in prescribing lower-cost medications.

By analyzing these dynamics and proposing solutions to balance affordability and innovation, this article underscores the critical need for policy adjustments to foster both pharmaceutical advancements and sustainable healthcare costs.